SAN DIEGO , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.
SAN DIEGO , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.
SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto , who has been serving as the Company’s Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr.
SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto , who has been serving as the Company’s Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr.
Tempol: A potential home treatment for COVID-19 ( https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19 ). Trial to begin shortly. SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a publication in the peer
Tempol: A potential home treatment for COVID-19 ( https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19 ). Trial to begin shortly. SAN DIEGO , Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced a publication in the peer
NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19 SAN DIEGO , Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment
NIH Researchers Contend that Tempol can be taken orally and may stop the replication of the virus that causes COVID-19 SAN DIEGO , Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment
Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline SAN DIEGO , Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a definitive agreement to sell a
Transaction Proceeds Will be Used for General Corporate Purposes and Funding Intended Acceleration of Pharmaceutical Pipeline SAN DIEGO , Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a definitive agreement to sell a
Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company's Board of Directors SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced that based on the Inspector
Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company's Board of Directors SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced that based on the Inspector
SAN DIEGO --(BUSINESS WIRE)--Jul. 13, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today urged its valued stockholders to vote to reelect all five members of the Company’s Board of Directors (the “Board”) at the upcoming Annual Meeting of Stockholders (the
SAN DIEGO --(BUSINESS WIRE)--Jul. 13, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today urged its valued stockholders to vote to reelect all five members of the Company’s Board of Directors (the “Board”) at the upcoming Annual Meeting of Stockholders (the
Asserts That Mr. Hammann — the Owner of Only 1,000 Shares — is Threatening the Company’s Strategic Progress Notes the Delaware Court of Chancery Denied Mr . Hammann’s Effort to Stop the Company From Sending Stockholders Proxy Materials and Holding its Annual Meeting as Scheduled Urges Stockholders
Asserts That Mr. Hammann — the Owner of Only 1,000 Shares — is Threatening the Company’s Strategic Progress Notes the Delaware Court of Chancery Denied Mr . Hammann’s Effort to Stop the Company From Sending Stockholders Proxy Materials and Holding its Annual Meeting as Scheduled Urges Stockholders
Believes Maintaining Board Continuity is Critical to Continuing to Pursue Progress Related to Tempol Urges Stockholders to Elect the Company’s Highly-Qualified Directors at the July 16 th Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Jun. 28, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
Believes Maintaining Board Continuity is Critical to Continuing to Pursue Progress Related to Tempol Urges Stockholders to Elect the Company’s Highly-Qualified Directors at the July 16 th Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Jun. 28, 2021-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
Highlights the Company’s High-Potential Products and Pipeline Notes the Current Board and Management Have Presided Over Significant Outperformance Over the Past Year Urges Stockholders to Sign, Date and Promptly Return the WHITE Proxy Card to Elect the Company’s Highly-Qualified Directors at the
Highlights the Company’s High-Potential Products and Pipeline Notes the Current Board and Management Have Presided Over Significant Outperformance Over the Past Year Urges Stockholders to Sign, Date and Promptly Return the WHITE Proxy Card to Elect the Company’s Highly-Qualified Directors at the
Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19 SAN DIEGO , June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of
Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19 SAN DIEGO , June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of
FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021 SAN DIEGO , June 09, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the
FDA Deems New Drug Application for ZIMHI Complete and Establishes a Target Action Date of November 12, 2021 SAN DIEGO , June 09, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the
NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19” Research Team Intends to Conduct Additional Studies, Including a Prospective Clinical Study for Tempol in the Treatment of COVID-19 SAN DIEGO , June 07, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals
NIH Researchers Contend “Tempol may be a Promising Oral Antiviral Treatment for COVID-19” Research Team Intends to Conduct Additional Studies, Including a Prospective Clinical Study for Tempol in the Treatment of COVID-19 SAN DIEGO , June 07, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals
NDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiated for Tempol for treatment of COVID-19 SAN DIEGO , June 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for
NDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiated for Tempol for treatment of COVID-19 SAN DIEGO , June 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for
SAN DIEGO , May 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose (the “Company”), today announced that, as expected, on May 25, 2021 , it
SAN DIEGO , May 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose (the “Company”), today announced that, as expected, on May 25, 2021 , it
SAN DIEGO , May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be held on Monday, May 17, 2021 , at 2 p.m. Pacific Time .
SAN DIEGO , May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be held on Monday, May 17, 2021 , at 2 p.m. Pacific Time .
SAN DIEGO , May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that the New Drug Application (NDA) was resubmitted to
SAN DIEGO , May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that the New Drug Application (NDA) was resubmitted to
SAN DIEGO , May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on
SAN DIEGO , May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on
Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 Management to host webcast/conference call today at 2 p.m. PDT / 5 p.m. EDT SAN DIEGO , April 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals
Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 Management to host webcast/conference call today at 2 p.m. PDT / 5 p.m. EDT SAN DIEGO , April 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals
SAN DIEGO , April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on
SAN DIEGO , April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on
SAN DIEGO , April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company’s New Drug Application (NDA) relating to its ZIMHI ™ high-dose naloxone injection product intended for the treatment of opioid overdose.
SAN DIEGO , April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company’s New Drug Application (NDA) relating to its ZIMHI ™ high-dose naloxone injection product intended for the treatment of opioid overdose.
SAN DIEGO , March 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes
SAN DIEGO , March 15, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes
SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the safety review of the Company’s Investigational New Drug (“IND”) application and has concluded that
SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") announced today that the U.S. Food and Drug Administration (“FDA”) has completed the safety review of the Company’s Investigational New Drug (“IND”) application and has concluded that
SAN DIEGO , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHI ™ high dose naloxone injection product candidate, intended for the treatment of
SAN DIEGO , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHI ™ high dose naloxone injection product candidate, intended for the treatment of
SAN DIEGO , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), today announced the closing of its underwritten public offering of 46,621,621 shares of its common stock, including 6,081,081 shares sold pursuant to the exercise in full of the underwriters' option to
SAN DIEGO , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), today announced the closing of its underwritten public offering of 46,621,621 shares of its common stock, including 6,081,081 shares sold pursuant to the exercise in full of the underwriters' option to
